Neurology News

Bristol Myers Squibb and Karuna Therapeutics Inc. announced a definitive merger agreement that includes Karuna’s lead asset, a muscarinic receptor agonist to treat schizophrenia and Alzheimer’s disease psychosis.

Meaningful progress is being made in the development of gene therapies for rare neurological diseases caused by single gene mutations.

A biotechnology company announced the first patient was dosed in its phase 2a clinical trial of intranasal foralumab, a monoclonal antibody treatment for those with non-active secondary-progressive multiple sclerosis.

A pharmaceutical company and a biotechnology firm have announced a development and license agreement for an investigational proprietary biologic combination therapy to treat amyotrophic lateral sclerosis.

A clinical-stage RNA medicines firm has announced the initiation of dosing in a phase 2 clinical trial of its investigational therapy for boys with Duchenne muscular dystrophy who are amenable to exon 53 skipping.

The FDA has cleared for marketing “the world’s first” cloud-based software for clinical analysis of neuromelanin-sensitive MRI scans, according to a press release from the manufacturer.

The FDA has approved AvertD, the first DNA test to identify an elevated risk for developing opioid use disorder, according to a press release.

The FDA has granted regulatory approval for Wainua for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, according to a press release.

A gene therapy company has announced updated interim data from ongoing United States and European phase 1/2 clinical trials of AMT-130 to treat Huntington’s disease.

A committee of the European Medicines Agency has recommended marketing authorization for Skyclarys to treat Friedreich’s ataxia in patients aged 16 years and older.